上海復旦張江生物醫藥股份有限公司

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code:1349)

INDICATIVE ANNOUNCEMENT
PASSING OF CONSISTENCY EVALUATION FOR DOXORUBICIN HYDROCHLORIDE LIPOSOME INJECTION

This announcement is made by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.* (the "**Company**") on a voluntary basis.

The board of directors (the "**Board**") of the Company is pleased to announce that, the Company has received the Notification of Approval for Supplementary Drug Application (《藥品補充申請批准通知書》) (notification No.: 2023B05505) of the quality and efficacy consistency evaluation of generic drugs for chemical injection (the "**Consistency Evaluation**") issued by the National Medical Products Administration of the PRC (the "**NMPA**"). The Consistency Evaluation application for Doxorubicin Hydrochloride Liposome Injection (LIBOd®, 里葆多®) (the "**Drug**") has been passed. Relevant information is as follows:

ABOUT THE DRUG

Drug name:	Doxorubicin Hydrochloride Liposome Injection
Specifications:	10ml:20mg
Application matter:	The quality and efficacy consistency evaluation of generic drugs
Registration type:	Class 6 generic drug (2007)
Acceptance No.:	CYHB2250452
Original drug approval number:	NMPN-H20084432
Applicant:	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd

LIBOd® (里葆多®) from Nano- drug platform of the Company for the treatment of tumors, the first generic drug from Doxil® in China and the first generic drug of nanomedicine at home and abroad, was launched for sale in August 2009 and it obtained favorable market response and reputation. The Drug is a new doxorubicin formula which adopts the advanced stealth liposomal encapsulation technology and has passive targeting characteristics. The Drug is a new generation of replacement for anthracycline drugs. In oncology, it has the advantages of enhancing efficacy and remarkably lowering the effects of cardiac toxicity, myelosuppression and hair-loss. The Drug is used for the treatment of AIDS-relating Kaposi's sarcoma, multiple myeloma, breast cancer and ovarian cancer, etc.

According to relevant policies and regulations, medical institutions have the opportunity to prioritize the procurement and clinical selection of drug varieties that have passed the Consistency Evaluation.

Due to the high-tech, high-risk and high-value-added characteristics of pharmaceutical products, and the influence of relevant policies, market environment and other factors, there are uncertainties in drug research and development. Investors are advised to make cautious decisions and pay careful attention to investment risks. The Company will actively facilitate the further related work of the Consistency Evaluation and fulfill its information disclosure obligations in a timely manner for subsequent progress in strict accordance with relevant regulations.

By Order of the Board

Zhao Da Jun

Chairman

As at the date on the publication of this announcement, the Board comprises:

Mr. Zhao Da Jun (Executive Director)
Ms. Xue Yan (Executive Director)
Mr. Shen Bo (Non-executive Director)
Ms. Yu Xiao Yang (Non-executive Director)
Mr. Wang Hong Guang (Independent Non-executive Director)
Mr. Lam Siu Wing (Independent Non-executive Director)
Mr. Xu Pei Long (Independent Non-executive Director)

Shanghai, the PRC

8 November 2023

** For identification purpose only*